Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial breakthroughs—or setbacks—can swing Aurinia Pharmaceuticals (AUPH) shares dramatically. Digging through dense risk factors, milestone payment tables, and drug safety sections in each filing is tough, especially when LUPKYNIS revenue guidance and AUR200 development costs are buried deep in footnotes. Investors often ask, “Where do I find the Aurinia Pharmaceuticals quarterly earnings report 10-Q filing?” or “How do I track Aurinia Pharmaceuticals insider trading Form 4 transactions?”
Stock Titan solves that problem. Our platform ingests every document the moment it hits EDGAR and provides Aurinia Pharmaceuticals SEC filings explained simply through AI-generated briefs that spotlight trial timelines, cash runway, and regulatory milestones. Whether you need the Aurinia Pharmaceuticals annual report 10-K simplified for long-term outlook, an Aurinia Pharmaceuticals 8-K material events explained alert after an FDA update, or Aurinia Pharmaceuticals Form 4 insider transactions real-time, the insight arrives in minutes. Understanding Aurinia Pharmaceuticals SEC documents with AI is now straightforward.
Use this page to:
- Receive instant alerts when an Aurinia Pharmaceuticals proxy statement executive compensation is posted.
- Compare trends with our Aurinia Pharmaceuticals earnings report filing analysis tools.
- Monitor Aurinia Pharmaceuticals executive stock transactions Form 4 ahead of key catalyst dates.
Every exhibit, footnote, and amendment is archived, cross-linked, and searchable. From shelf registrations to clinical-trial updates, you get comprehensive coverage, real-time updates, and AI-powered summaries that turn complex biotech disclosures into actionable knowledge.
Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.
The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.
Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.
The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.
Aurinia Pharmaceuticals (AUPH) reported stronger Q3 2025 results, led by continued LUPKYNIS growth and lower operating costs. Total revenue was $73.5 million, up from $67.8 million a year ago, with net product sales of $70.6 million. Net income rose to $31.6 million from $14.4 million as SG&A spending declined following 2024 restructuring actions. Gross margin was 89% for the quarter.
Year to date, revenue reached $205.9 million and net income was $76.4 million. Operating cash flow for the nine months was $90.0 million. Cash, cash equivalents, restricted cash and investments were $351.8 million as of September 30, 2025. The company repurchased 12.2 million common shares year to date under its authorized program. Common shares outstanding were 131,840,559 as of November 3, 2025.
This Amendment No. 16 to the Schedule 13D reports the holdings and recent transactions by ILJIN-related reporting persons in Aurinia Pharmaceuticals Inc.'s common shares. Chin Kyu Huh beneficially owns 6,535,141 shares, equal to 5.0% of the outstanding class, and certain ILJIN entities report shared voting and dispositive power over 5,411,533 shares (4.1%). The filing states small purchases by family members and material secondary-market sales by ILJIN SNT and a family member, with per-share prices disclosed.
The filing also states the Reporting Persons may be deemed a group for Section 13(d)(3) purposes while disclaiming certain beneficial ownerships among family members and entities. All percentage calculations are based on 131,629,546 shares outstanding as reported by the issuer.
Aurinia Pharmaceuticals Inc. (AUPH) – Form 4 insider buying
Director Kevin Tang, through Tang Capital Partners LP and Tang Capital Partners International LP, purchased a total of 1,300,000 common shares in three open-market transactions dated 1-5 Aug 2025 (transaction code P). Weighted-average purchase prices were:
- 1,000,000 sh @ $10.12 (range $9.23-$10.50)
- 100,000 sh @ $11.34 (range $11.11-$11.48)
- 200,000 sh @ $11.68 (range $11.49-$11.80)
FAQ
What is the current stock price of Aurinia Pharmace (AUPH)?
What is the market cap of Aurinia Pharmace (AUPH)?
